Article

Thiazole-Bearing 4-Thiazolidinones as New Anticonvulsant Agents

Mariia Mishchenko 1, Sergiy Shtrygol 1, Danylo Kaminskyy 2 and Roman Lesyk 2,3,*

1 Department of Pharmacology, National University of Pharmacy, Kulykovska 12, 61168 Kharkiv, Ukraine; mishmasha@gmail.com (M.M.); shtrygol@ukr.net (S.S.)
2 Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine; dankaminskyy@gmail.com
3 Department of Public Health, Dietetics and Lifestyle Disorders, Faculty of Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225 Rzeszow, Poland
* Correspondence: dr_r_lesyk@org.lviv.net; Tel.: +380-32-275-5966

Received: 19 February 2020; Accepted: 18 March 2020; Published: 24 March 2020

Abstract: Here, we describe the synthesis and anticonvulsant activity of thiazole-bearing hybrids based on 2-imino-4-thiazolidinone and 2,4-dioxothiazolidine-5-carboxylic acid cores. The structure of target compounds was based on the following: (i) A combination of two thiazole cores; (ii) similarity to ralitolin’s structure; (iii) the compliance with structural requirements for the new anticonvulsants. Target compounds were synthesized via known approaches based on Knoevenagel reaction, alkylation reaction, and one-pot three-component reaction. Anticonvulsant properties of compounds were evaluated in two different models—pentylenetetrazole-induced seizures and maximal electroshock seizure tests. Among the tested compounds 5Z-(3-nitrobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one Ib, 2-[2,4-dioxo-5-(thiazol-2-ylcarbamoylmethyl)-thiazolidin-3-yl]-N-(2-trifluoromethylphenyl)acetamide IId and (2,4-dioxo-5-(thiazol-2-ylcarbamoylmethylene)-thiazolidin-3-yl)acetic acid ethyl ester Iij showed excellent anticonvulsant activity in both models. The directions of compounds modification based on SAR aspects were discussed. The results of the study provide a basis for further study of the anticonvulsant properties of selected thiazole-thiazolidinones.

Keywords: 4-thiazolidinones; thiazoles; synthesis; anticonvulsant activity

1. Introduction

Epilepsy is one of the most common chronic neurological diseases, affecting up to 1% of the human population [1]. According to the WHO, more than 50 million people worldwide suffer from epilepsy [2]. Over the last decades, more than 20 new anti-epileptic drugs from different chemical groups have been marketed, namely: Eslicarbazepine acetate [3], perampanel [4], ezogabine [5] etc. However, a significant part of patients cannot obtain a stable anticonvulsant effect under monotherapy [6], and about 30% of patients have refractory epilepsy and need treatment with drug combinations [7,8]. Increasing the frequency of attacks and side effects, the transformation of attacks and deterioration of the electroencephalogram are observed in some patients under anti-epileptic drug treatment. This is largely due to inadequate effectiveness of anticonvulsants, the need for their high doses, and as a result, their dose-dependent side effects, namely violations of behavioral reactions, emotional state, cognitive abilities, the development of encephalopathy, and mental disorders [9]. Thus, the search for new efficient and safety anticonvulsants is of special interest.

4-Thiazolidinones are a known class of drug-like molecules and improved drugs with a broad spectrum of biological effects [10,11], including anticonvulsant [12,13]. Thiazolidinone frame
is considered as cyclic mimic of thiosemicarbazides and thioureas as well as (bio)isoster of hidantoin (imidazolidine-2,4-dione) [11]—approved scaffolds of known anticonvulsants and privileged (sub)structures for new anticonvulsants design [14–16]. “Fixation” of thiosemicarbazide/thiourea in a cyclic structure (thiazolidinone/thiazole core) and further optimization leads to activity increasing [17]. Moreover, the tendency to increase activity in the row: Thiazole–oxazole–4-thiazolidinone derivatives was described [18,19]. One of the main achievements in the anticonvulsant thiazolidinones area is the ralitolin - (2Z)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-4-oxo-1,3-thiazolidine-2-ylidene)-acetamide and phenytoin - 5,5-diphenyl-2,4-imidazolidinedione, which are proved anticonvulsant drugs. Moreover, thiazolidinone derivatives correspond to the structural requirements to new anticonvulsant structure: (i) Contain cyclic imide or N-CO-CN fragments [20]; (ii) involve the combination of two aromatic rings as hydrophobic domain; (iii) contain N=C-NH moiety as hydrogen bonding domain; (iv) contain carbonyl group as the electron donor group [21–26] (Figure 1).

Among different thiazolidinone subtypes, 5-substituted 2-amino(imino)-4-thiazolidinones [27] and 2-R-substituted-4-thiazolidinones are the most discussed compounds with confirmed anticonvulsant activity [28–31]. One of the efficient approaches for the design of new anticonvulsants is the combination of different heterocyclic cores, especially (thi)azoles in one molecule within a hybrid pharmacophore approach [19,21,31–36]. Highly active compounds with anticonvulsant activity have been identified among compounds combining thiazolidinone and quinazoline-4(3H)-one [37], thiobarbituric acid, triazole [27], benzodiazepine [19], coumarin [18], thiazole [31], thiadiazole [21], indole [30] fragments, etc. Very little data were published regarding the molecular mode/mechanism of action of thiazolidinone-based anticonvulsant agents. The anticonvulsant activity has been related to the ability to inhibit the oxidation of Krebs’ cycle intermediates (pyruvate, a-ketoglutarate, citrate and b-hydroxybutyrate), in this study the prevalence of phenyl ring at C2 position was showed [38].

The present work is an extension of our ongoing efforts towards a search for new 4-thiazolidinone-based anticonvulsant agents [22,39]. Here, we addressed the design and synthesis of thiazole-thiazolidinones hybrids and evaluation of their anticonvulsant effects.

Figure 1. Structural features and “pharmacophore fragments” of the known anticonvulsants (fragments containing hydrophobic aromatic systems (A), a hydrogen-binding domain (B), an electron-donor fragment (C), a distal aromatic ring (D) adapted from [22,26].
2. Materials and Methods

2.1. Chemistry

The starting (2,4-dioxothiazolidin-5-yl)-acetic acid, (2,4-dioxothiazolidin-5-ylidene)-acetic acid [40,41], and 2-(thiazol-2-ylimino)-thiazolidin-4-one [42] were obtained according to the known methods. Melting points were measured in open capillary tubes on a BUCHI B-545 melting point apparatus and were uncorrected. The elemental analyses (C, H, N) were performed using the Perkin-Elmer 2400 CHN analyzer and were within ±0.4% of the theoretical values. IR spectra were recorded in KBr on a Nicolet iN10FX spectrometer. The 1H NMR spectra were recorded on Varian Gemini 400 MHz and 13C NMR spectra on Varian Mercury-400 100 MHz in DMSO-\textit{d}_6 using tetramethylsilane as an internal standard. Chemical shifts are reported in ppm units with use of δ scale. Mass spectra were obtained using electrospray ionization (ESI) techniques on an Agilent 1100 Series LCMS.

2.2. General Procedure for the 5-(Het)Arylidene-2-(Thiazol-2-yl)Amino(Imino)-4-Thiazolidinones Synthesis (I)

A mixture of appropriate 2-(thiazol-2-ylimino)-thiazolidin-4-one (5 mmol), aromatic aldehyde or isatin (5 mmol), and anhydrous sodium acetate (5 mmol, 0.41 g) in glacial acetic acid (20 mL) was heated under reflux for 3 h. Precipitate obtained after cooling was filtered off, washed with methanol and recrystallized with DMF:ethanol (1:2) mixture or acetic acid.

5Z-(4-Fluorobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one (Ia). Yield 76%, mp 238–240 °C. IR (cm\(^{-1}\), KBr): 3080 (NH), 1716 (C=O), 1592 (C=N). 1H NMR (400 MHz, DMSO-\textit{d}_6): δ 7.70 (d, 1H, \(J = 3.9\) Hz, thiazol.), 7.25 (t, 2H, \(J = 7.8\) Hz, arom.), 7.60 (d, 1H, \(J = 4.0\) Hz, thiazol.), 7.65 (s, 1H, CH=), 7.70 (d, 2H, \(J = 7.9\) Hz, arom.), 12.40 (brs, 1H, NH). 13C NMR (100 MHz, DMSO-\textit{d}_6): δ 169.2, 167.3, 160.6 (d, \(J = 259\) Hz), 159.3, 140.9, 133.0, 132.9, 131.1, 124.7, 118.0, 117.0 (d, \(J = 22\) Hz). LCMS (ESI) m/z 306 (98.4%, (M + H)\(^+\)). Calcd. for C\(_{13}\)H\(_8\)FN\(_3\)OS\(_2\): C, 51.14; H, 2.64; N, 13.76; Found: C, 51.00; H, 2.40; N, 14.00%.

5Z-(3-Nitrobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one (Ib). Yield 82%, mp 216–218 °C, lit 231–233 °C [43]. IR (cm\(^{-1}\), KBr): 3085 (NH), 1707 (C=O), 1599 (C=N). 1H NMR (400 MHz, DMSO-\textit{d}_6): δ 7.53 (d, 1H, \(J = 4.1\) Hz, thiazol.), 7.73 (d, 1H, \(J = 4.0\) Hz, thiazol.), 7.87 (s, 1H, CH=), 7.85 (t, 1H, \(J = 8.0\) Hz, arom.), 8.07 (d, 1H, \(J = 8.2\) Hz, arom.), 8.28 (d, 1H, \(J = 8.2\) Hz, arom.), 8.50 (s, 1H, arom.), 12.80 (brs, 1H, NH). 13C NMR (100 MHz, DMSO-\textit{d}_6): δ 173.1, 168.9, 166.9, 148.7, 141.0, 135.9, 131.3, 129.6, 124.9, 124.6, 118.2, 118.1, 110.8. LCMS (ESI) m/z 333 (100%, (M + H)\(^+\)). Calcd. for C\(_{13}\)H\(_6\)N\(_2\)O\(_3\): C, 46.98; H, 2.43; N, 16.86; Found: C, 46.80; H, 2.30; N, 17.10%.

5Z-(4-Dimethylaminobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one (Ic). Yield 75%, mp 249–251 °C. 1H NMR (400 MHz, DMSO-\textit{d}_6): δ 3.10 (s, 6H, 2\(^\ddagger\)CH\(_3\)), 6.85 (d, 2H, \(J = 7.9\) Hz, arom.), 7.21 (d, 1H, \(J = 4.0\) Hz, thiazol.), 7.45 (d, 2H, \(J = 8.0\) Hz, arom.), 7.55 (s, 1H, CH=), 7.60 (d, 1H, \(J = 4.0\) Hz, thiazol.), 12.40 (brs, 1H, NH). 13C NMR (100 MHz, DMSO-\textit{d}_6): δ 170.1, 168.0, 159.6, 150.6, 149.1, 139.2, 131.0, 126.5, 118.6, 112.4, 107.9, 39.5. LCMS (ESI) m/z 331 (99.6%, (M + H)\(^+\)). Calcd. for C\(_{15}\)H\(_8\)N\(_2\)O\(_3\): C, 54.52; H, 4.27; N, 16.96; Found: C, 54.60; H, 4.50; N, 16.70%.

3-[4-Oxo-2-(thiazol-2-ylimino)thiazolidin-5-ylidene]-1,3-dihydroindol-2-one (Id). Yield 81%, mp > 250 °C. 1H NMR (400 MHz, DMSO-\textit{d}_6): δ 6.90 (d, 1H, \(J = 4.2\) Hz, thiazol.), 7.00 (t, 1H, \(J = 8.8\) Hz, arom.), 7.32 (t, 1H, \(J = 8.7\) Hz, arom.), 7.40 (d, 1H, \(J = 4.0\) Hz, thiazol.), 7.70 (d, 1H, \(J = 8.7\) Hz, arom.), 8.85 (d, 1H, \(J = 8.7\) Hz, arom.), 12.80 (brs, 1H, NH). 13C NMR (100 MHz, DMSO-\textit{d}_6): δ 168.7, 168.4, 165.3, 156.8, 140.9, 132.5, 132.2, 131.4, 128.2, 118.6, 117.4, 110.4. LCMS (ESI) m/z 329 (96.5%, (M + H)\(^+\)). Calcd. for C\(_{14}\)H\(_8\)N\(_2\)O\(_3\): C, 51.21; H, 2.46; N, 17.06; Found: C, 51.00; H, 2.30; N, 17.30%.

3-Allyl-5-(4-hydroxybenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one (Ie). A mixture of the 1-allyl-3-thiazol-2-yl-thioure (5 mmol, 1.0 g), p-hydroxybenzaldehyde (5 mmol, 0.61 g), chloroacetic acid (5 mmol, 0.47 g), and sodium acetate (5 mmol, 0.41 g) in 20 mL of acetic acid was heated under reflux for 3 h. Formed precipitate was filtered off, washed with acetic acid, water, ethanol, and diethyl ether and then recrystallized from a mixture of DMF:ethanol (1:2). Yield 69%, mp 219–221 °C. 1H
NMR (400 MHz, DMSO-d$_6$): $\delta$ 4.53 (d, 2H, $J = 4.8$ Hz, CH$_2$), 5.18 (m, 1H, CH$_2$), 5.21 (d, 1H, $J = 9.2$ Hz, CH$_2$), 5.90 (m, 1H, CH), 7.42 (d, 1H, $J = 4.2$ Hz, thiazol), 7.68 (d, 1H, $J = 4.1$ Hz, thiazol), 6.94 (d, 2H, $J = 8.1$ Hz, arom.), 7.50 (d, 2H, $J = 8.0$ Hz, arom.), 7.73 (s, 1H, CH), 10.23 (s, 1H, OH).$^{13}$C NMR (100 MHz, DMSO-d$_6$): $\delta$ 169.0, 165.9, 165.9, 160.4, 154.5, 140.8, 133.9, 133.2, 131.9, 124.7, 118.2, 117.5, 116.9, 45.2. LCMS (ESI) m/z 344 (96.4%, (M + H)$^+$). Calcd. for C$_{16}$H$_{13}$N$_3$O$_5$S$_2$: C, 55.96; H, 3.82; N, 12.24; Found: C, 55.70; H, 3.50; N, 12.50%.

2.3. General Method for Amides of 2,4-Dioxothiazolidine-5-Carboxylic Acids Synthesis (II)

A mixture of 5 mmol of 2,4-dioxothiazolidine-5-carboxylic acid or 2,4-dioxothiazolidin-5-ylidene)-acetic acid, 12 mL of thionyl chloride in 30 mL of dioxane was heated under reflux for 2 h, cooled, and treated with 100 mL of hexane. The precipitate was separated by filtration. To the solution of 5 mmol of the corresponding 2-aminozoal, 1 mL of triethylamine in 10 mL of anhydrous dioxane the solution of appropriate 5 mmol acid chloride in 10 mL of the same solvent was added. The mixture was heated for 20 min at 90 °C, cooled and diluted with 100 mL of water. The formed precipitate was filtered and recrystallized from an appropriate solvent.

$N$-(Thiazol-2-yl)-2-(2,4-dioxothiazolidin-5-yl)-acetamide (IIa). Spectral and analytical data were described [40].

$N$-(Thiazol-2-yl)-2-(2,4-dioxothiazolidin-5-ylidene)-acetamide (IIIf). Yield 72%, mp > 250 °C. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ 7.12 (d, 1H, $J = 4.1$ Hz, thiazol), 7.43 (d, 1H, $J = 4.0$ Hz, thiazol), 7.50 (s, 1H, CH), 11.2 (s, 1H, NH), 12.80 (brs, 1H, NH).$^{13}$C NMR (100 MHz, DMSO-d$_6$): $\delta$ 169.5, 167.0, 164.6, 156.1, 138.7, 137.4, 121.3, 115.4. LCMS (ESI) m/z 256 (98.4%, (M + H)$^+$). Calcd. for C$_8$H$_8$N$_3$O$_3$S$_2$: C, 37.64; H, 1.97; N, 16.46; Found: C, 37.50; H, 1.80; N, 16.70%.

2-(2,4-Dioxothiazolidin-5-ylidene)-N-(5-methyl-[1,3,4]thiadiazol-2-yl)-acetamide (IIg). Yield 70%, mp > 250 °C. IR (cm$^{-1}$, KBr):3043 (NH), 1692, 1666, 1620, (C=O), 1573. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ 2.67 (s, 3H, CH$_3$), 7.25 (s, 1H, CH=), 12.82 (brs, 1H, NH), 13.21 (s, 1H, NH).$^{13}$C NMR (100 MHz, DMSO-d$_6$): $\delta$ 170.6, 166.8, 162.4, 160.6, 158.6, 141.8, 118.5, 15.4. LCMS (ESI) m/z 271 (98.3%, (M + H)$^+$). Calcd. for C$_8$H$_8$N$_3$O$_3$S$_2$: C, 35.55; H, 2.24; N, 20.73; Found: C, 35.40; H, 2.60; N, 20.40%.

$N$-[5-(4-Chlorobenzyl)-thiazol-2-yl]-2-(2,4-dioxothiazolidin-5-ylidene)-acetamide (IIh). Yield 74%, mp > 230 °C. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ 4.05 (s, 2H, CH$_2$), 7.20–7.32 (m, 6H, arom., CH), 12.62 (brs, 1H, NH), 12.76 (s, 1H, NH).$^{13}$C NMR (100 MHz, DMSO-d$_6$): $\delta$ 170.8, 166.8, 158.4, 154.6, 146.6, 145.7, 140.8, 139.7, 131.6, 129.0, 31.6. LCMS (ESI) m/z 380/382 (99.8%, (M + H)$^+$). Calcd. for C$_{16}$H$_{13}$F$_3$N$_3$O$_5$S$_2$: C, 47.43; H, 2.65; N, 11.06; Found: C, 47.20; H, 2.60; N, 10.90%.

2-(2,4-Dioxothiazolidin-5-ylidene)-N-[5-(3-trifluoromethylbenzyl)-thiazol-2-yl]-acetamide (III). Yield 73%, mp 262–264 °C. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ 4.22 (s, 2H, CH$_2$), 6.84 (s, 1H, CH), 7.45 (s, 1H, arom.), 7.62–7.71 (m, 4H, arom.), 12.35 (brs, 1H, NH), 12.83 (s, 1H, NH).$^{13}$C NMR (100 MHz, DMSO-d$_6$): $\delta$ 170.0, 168.1, 163.6, 155.6, 140.3, 138.7, 137.3, 131.7, 131.4, 131.3 (q, $J = 26$ Hz), 125.4 (q, $J = 280$ Hz), 124.6, 120.8, 119.6, 114.7, 35.8. LCMS (ESI) m/z 414 (100%, (M + H)$^+$). Calcd. for C$_{16}$H$_{10}$F$_3$N$_3$O$_5$S$_2$: C, 48.49; H, 2.44; N, 10.16; Found: C, 48.20; H, 2.50; N, 10.40%.

2.4. General Procedure for N3-Substituted 2,4-Dioxothiazolidine-5-Carboxamides Synthesis

A suspension of 10 mmol of an appropriate 2,4-dioxothiazolidine-5-carboxamide (IIa or IIIf) in 15 mL ethanol was treated with 11 mmol (0.62 g) of KOH in 8 mL of the same solvent. The mixture was stirred for 2 h, and the precipitate was separated, washed with filtration, washed with ethanol and ether. A mixture of N-potassium salt of appropriate 2,4-thiazolidinedione (5 mmol), N-substituted chloroacetamide or 4-fluorobenzyl chloride or chloroacetic acid ethyl ester (5.5 mmol), catalytic amount of potassium iodide and potassium carbonate in 15 mL of DMF-EtOH misxture (1:2) was heated under reflux for 3 h. Reaction product was filtered off after cooling and pouring into water, washed with water, ethanol, and diethyl ether and recrystallized.

2-[3-(4-Fluorobenzyl)-2,4-dioxothiazolidin-5-yl]-N-thiazol-2-yl-acetamide (IIb). Yield 79%, mp 236–238 °C. $^1$H NMR (400 MHz, DMSO-d$_6$): $\delta$ 3.12 (m, 1H, CHCH$_2$), 3.42 (dd, 1H, $J = 15.9$ Hz,
Adult random-bred albino-mice of either sex weighing 18–25 g, which were kept under the standard sanitary-hygienic conditions in the vivarium of the Central Research Laboratory of the National Pharmaceutical University (Ukraine), were used in the experiments. All animal procedures were approved by the institutional animal care and use committee and corresponding to the Law of Ukraine. During the experiment, the rules and principles adopted by the Helsinki Declaration on Humane Animal Welfare (2000), the Directive of the Council of the European Union on the protection of animals used for scientific purposes (2010) were observed. The animals were randomized into the next groups: Group 1—control group; Group 2—experimental group—mice treated with studied compounds or reference drugs.

The synthesized compounds were screened for their anticonvulsant activity by the pentylentetrazole-induced (PTZ) seizures test and maximal electroshock seizure (MES) test [44,45]. Animals were administered the tested compounds once in the form of a thin suspension stabilized with polysorbate-80 (TWEEN-80), at a dose of 100 mg/kg intragastrically.

2.5. Pharmacology

Adult random-bred albino-mice of either sex weighing 18–25 g, which were kept under the standard sanitary-hygienic conditions in the vivarium of the Central Research Laboratory of the National Pharmaceutical University (Ukraine), were used in the experiments. All animal procedures were approved by the institutional animal care and use committee and corresponding to the Law of Ukraine. During the experiment, the rules and principles adopted by the Helsinki Declaration on Humane Animal Welfare (2000), the Directive of the Council of the European Union on the protection of animals used for scientific purposes (2010) were observed. The animals were randomized into the next groups: Group 1—control group; Group 2—experimental group—mice treated with studied compounds or reference drugs.

The synthesized compounds were screened for their anticonvulsant activity by the pentylentetrazole-induced (PTZ) seizures test and maximal electroshock seizure (MES) test [44,45]. Animals were administered the tested compounds once in the form of a thin suspension stabilized with polysorbate-80 (TWEEN-80), at a dose of 100 mg/kg intragastrically.
In the PTZ test, in which seizures were induced by suppression of GABA-ergic inhibitory processes, sodium valproate (Depakin, Sanofi-Aventis, Gentilly, France) as a reference drug was administrated intragastrically (300 mg/kg) as an oral syrup. In the control group, the animals received purified water in an appropriate volume. Pentylenetetrazole (Corazol, Sigma-Aldrich, St. Louis, MO, USA) in the form of water solution (90 mg/kg) was injected subcutaneously 30 min after compound application. Subsequently, each mouse was placed in a separate cylindrical plastic container (5 L) and continuously monitored for 60 min.

MES test was used to evaluate the ability of compounds to prevent the generalization of seizure. Electroshock was applied via corneal electrodes. The ability of the compounds to prevent seizures was associated with the prevention of the spread of impulse through the nerve tissues. In the MES test, electric current-50 mA, a frequency 50 Hz during 0.2 s was used 30 min after the application of the tested compounds. Carbamazepine (Finlepsin, TEVA-Pharmaceuticals, Petah Tikva, Israel) was used as a reference drug and was administered intragastrically (40 mg/kg) in the form of a thin water suspension stabilized with a Tween-80 (polysorbate 80). The observation lasted 60 min. Latency of the convulsions; the number of clonic-tonic convulsions in one mouse; % of animals with clonic and tonic convulsions; the duration of the convulsive period (from the first to the last attack); and the lifetime of the animals before death (in mice with a lethal outcome) were calculated. The severity of seizures was evaluated according to a scale ranging from 1 to 6: 1—trembling; 2—circus movement; 3—clonic seizures; 4—clonic-tonic seizures with a lateral position; 5—tonic extension; 6—tonic extension leading to the animal’s death. When seizures were not observed within 1 h, it was considered that the latent period was 60 min. The protection of animals from the development of clonic and tonic seizures and lethality were treated as the most significant indicators of anticonvulsant activity of the compounds [44].

Acute toxicity. The experiments were conducted on white male mice weighing 23–25 g. Compounds were dissolved in saline solution (0.9% NaCl) with 1–2 drops of polysorbate 80 (Tweem-80), after dissolution they were administered via intraperitoneal route. The LD$_{50}$ was evaluated for 4 or 5 different doses each on 6 animals and calculated by the Litchfield-Wilcoxon method [46,47].

Statistical analysis was carried out using a Statistica 10.0 by the methods of variation statistics. The average values and standard errors were calculated. The significance of the differences between groups was estimated according to the Student’s criterion (t) in the case of normal distribution, and according to the nonparametric Mann-Whitney criterion (U) in the case of the absence of normal distribution. The results, which were determined in an alternative form (presence/absence of a certain feature), were evaluated using the Fisher’s criterion (ϕ) [48].

3. Results and Discussion

The design of molecule structure of target compounds was based on: Our former findings [22,39]; the compliance with structural requirements for potential anticonvulsants (see above); combination of thiazole and thiazolidinone cores in one molecule [49,50]; structural similarity with ralitolin (Figure 2).
Target compounds belong to the two 4-thiazolidinone subtypes-2-imino-4-thiazolidinones I and 5-carboxymethyl(idene)-2,4-thiazolidinediones II. 2-Imino-4-thiazolidinones I were synthesized based on known approaches started from N-thiazolylchloroacetamide or disubstituted thiourea [43,51]. Target compounds Ib–Id were obtained in the Knoevenagel reaction condition (Scheme 1), compound Ie was synthesized in one-pot three-component reaction of substituted thiourea, aldehyde and chloroacetic acid [51].

![Scheme 1](image)

**Scheme 1.** Synthesis of 2-amino(imino)-4-thiazolidinones I. Reagents and conditions: (i) 2-(thiazol-2-ylimino)-thiazolidin-4-one (1.0 equiv), aromatic aldehyde (1.0 equiv), AcONa (1.0 equiv), AcOH, reflux, 3 h; (ii) 1-allyl-3-thiazol-2-yl-thiourea (1.0 equiv), p-hydroxybenzaldehyde (1.0 equiv), ClCH$_2$COOH (1.0 equiv), AcONa (1.0 equiv), AcOH, reflux, 3 h.

Synthesized 4-thiazolidinones, bearing hydrogen atom on an exocyclic nitrogen atom (N3) can exist in the two tautomeric forms – 2-imino-4-thiazolidinones (exocyclic C=N bond) and 2-amino-4-thiazolidinones (endocyclic C=N bond) [52,53]. The form of compounds presentation (imino-form) was argued by previous data [51]. All synthesized compounds are in Z-isomeric form (thiazolidinone C5 double bond) [11,51,52].

(2,4-Dioxothiazolidin-5-yl)-acetic acid was used as starting reagents for synthesis of 2,4-thiazolidinedione-5-carboxylic acids amides II via known approach [40,54] (Scheme 2).

![Scheme 2](image)

**Scheme 2.** Synthesis of 2,4-thiazolidinedione-5-carboxylic acids amides II. Reagents and conditions: (i) 1—2,4-dioxothiazolidin-5-carboxylic acid (1.0 equiv), SOCl$_2$, dioxane, reflux 1 h; 2—acid chloride (1.0 equiv.), amino-azole (1.0 equiv.), triethylamine (1.0 equiv.), dioxane, 30 min 90 °C; (ii) 1—appropriate 2,4-thiazolidinedione-5-carboxamide (1.0 equiv.), KOH (1.1 equiv.), EtOH, reflux 2h, 2—potassium salt of appropriate 2,4-azolidinedione-5-carboxamide (1.0 equiv), appropriate chloride (1.1 equiv.), cat. amount KI and K$_2$CO$_3$, DMF:EtOH (1:2) mixture reflux, 3 h.
Amides Ila and IIff were utilized in the acylation reaction for the target N3-substituted compounds (IIb-IIle, IIIf) synthesis. Structure of compounds was confirmed by physico-chemical data (see above).

The evaluation of anticonvulsant activity of the tested compounds was undertaken within the known anticonvulsant drug development program protocol [55]. The procedure involved PTZ-induced seizures and MES-test. For anticonvulsant activity study, N-unsubstituted 2-imino-thiazolidinones were used in the form of N-potassium salts.

At the first stage, a PTZ-induced seizures model was used. The mechanism of attack development was based on the suppressive effect of PTZ on GABA-receptors, resulting in a reduction in the inhibitory effect of GABA in the central nervous system [45]. Sodium valproate was used as a reference drug (Table 1). The anticonvulsant activity of the latter was associated with blockade of sodium channels, increased activity of glutamate decarboxylase, and suppression of GABA transaminase, which led to an increase in the level of GABA in the central nervous system [56]. At the experimental conditions, sodium valproate (300 mg/kg) showed good anticonvulsant effect: A significant decrease of the latent period of seizure development (by 6 times comparing to control); decrease (2.4 times) of the amount of clonic-tonic seizures per animal; decrease of the percentage of mice with clonic and tonic seizures (50 vs. 100% and 33.33 vs. 91.67%, \( p < 0.01 \)); decreasing of the severity of the seizures by 2.8 times; decrease of the duration of the seizure period by 1.9 times; and decrease of the mortality. Among the tested compounds, three of the most active compounds Ib, IId, IIj were identified.

Compound IIj significantly reduced (by 3.3 times) the duration of the convulsive period (2.93 ± 1.99 min vs. 9.68 ± 1.96 min, \( p < 0.05 \)) and the level of mortality by 2.5 times (33.33% vs. 83.33%, \( p < 0.05 \)). The latent period, the proportion of animals with clonic seizures and severity of convulsion were decreased, but the compound’s effect was inferior to the sodium valproate.

Compound IId significantly reduced (1.8 times) the proportion of animals with clonic seizures (50.00% vs. 91.67%, \( p < 0.05 \)), reduced (1.5 times) the severity of the seizure (3.67 ± 0.88 vs. 5.58 ± 0.29 points, \( p < 0.05 \)) and mortality by 5 times (16.67% vs. 83.33%, \( p < 0.01 \)). The effect of compound IId was similar to the reference drug.

Among tested compounds, the compound Ib, which affected all of the studied parameters at the level of the sodium valproate, was the most active. It significantly reduced the latent period (43.59 ± 10.58 min vs. 5.63 ± 0.76 min, \( p < 0.05 \)); the amount of clonic-tonic convulsion per animal was 6.8 times lower (0.50 ± 0.34 vs. 3.42 ± 0.47, \( p < 0.01 \)); the portion of animals with clonic and tonic seizures was lower at 3 and 5.5 times, respectively (33.33% vs. 100% and 16.67% vs. 91.67%, \( p < 0.01 \)); the severity of the convulsion was 3.7 times lower (1.50 ± 1.03 vs. 5.58 ± 0.29, \( p < 0.01 \)) as well as the duration of the convulsive period (6.9 times, 1.40 ± 1.38 min vs. 9.68 ± 1.96 min, \( p < 0.01 \)). The mortality under compound’s action was decreased at 66.7% (16.67% vs. 83.33%, \( p < 0.01 \)). These were confirmed by our primary data [22].

Seven compounds: Ie, IIb, IIff, IIe, IIg, IIIh, and IIi did not show either anticonvulsant or pro-convulsant activity. For the two compounds Ia and Ic, the minor anticonvulsant properties were established since they significantly affected only one or two of the studied parameters. There was a significant decrease in the control of the number of convulsion per animal and the decrease in the duration of the convulsive period under compound Ia action. Compound Ic contributed to the lengthening of the latent period and the decrease in the amount of clonic-tonic convulsions per mouse.

Compounds Id and IIc showed pro-convulsant properties. Compound IIc, which showed moderate pro-convulsant properties, was characterized by a significant reduction in the life of animals before death and, accordingly, the duration of the convulsive period. In all animals, under compound IIc action the most severe tonic convulsions were observed. Compound Id induced the development of tonic seizures in 100% of cases, indicating its pro-convulsant properties.
Table 1. Anticonvulsant effect of tested compounds in PTZ model.

| Group | n  | Latent Period, min | Number of Clonic-Tonic Seizures per Mouse | % of Mice with Seizures | Severity of Seizures, Points | Period of Seizures, min | Time to Death, min | Mortality, % |
|-------|----|--------------------|------------------------------------------|--------------------------|-----------------------------|--------------------------|-------------------|--------------|
| Control | 12 | 5.63 ± 0.76        | 3.42 ± 0.47                              | 100                      | 5.58 ± 0.29                 | 9.68 ± 1.96             | 15.71 ± 2.70     | 83.33        |
| SV     | 12 | 34.06 ± 7.87 **    | 1.42 ± 0.53 *                            | 50 **                    | 2.00 ± 0.64 **              | 5.10 ± 2.24 *           | 20.9             | 8.33 **      |
| Ia     | 6  | 9.58 ± 2.11        | 1.50 ± 0.34 **                            | 100 **                   | 5.50 ± 0.50 **              | 2.92 ± 2.62 *           | 12.61 ± 3.32     | 83.33 **     |
| Ib     | 6  | 43.59 ± 10.58 *    | 0.50 ± 0.34 **                            | 33.33 **                 | 1.50 ± 1.03 **              | 1.40 ± 1.38 **          | 26.9             | 16.67 **     |
| Ic     | 6  | 20.26 ± 8.57 *     | 1.50 ± 0.34 **                            | 83.33                    | 4.17 ± 0.98                 | 4.66 ± 2.99             | 11.72 ± 4.15     | 50.00        |
| Id     | 6  | 3.89 ± 1.38 **     | 2.17 ± 0.31                               | 100 **                   | 5.67 ± 0.33 **              | 6.87 ± 2.37             | 10.76 ± 2.31     | 83.33 **     |
| Ie     | 6  | 12.73 ± 9.46 #     | 2.67 ± 0.88                               | 83.33                    | 4.17 ± 0.98                 | 7.97 ± 2.92             | 9.51 ± 3.10      | 50.00        |
| IIb    | 6  | 15.55 ± 9.20       | 1.50 ± 0.56 *                            | 83.33                    | 4.67 ± 0.99 #               | 4.41 ± 3.65 *           | 10.35 ± 5.46     | 66.67 **     |
| IIc    | 6  | 5.51 ± 2.30 #      | 2.17 ± 0.75                               | 100 **                   | 5.33 ± 0.42 **              | 2.25 ± 1.36 *           | 4.91 ± 1.62 *    | 66.67 **     |
| IIId   | 6  | 16.92 ± 8.90       | 2.33 ± 0.76                               | 83.33                    | 3.67 ± 0.88 *               | 7.64 ± 2.79             | 9.23             | 16.67 **     |
| IIe    | 6  | 13.33 ± 9.37       | 2.17 ± 0.70                               | 83.33                    | 4.17 ± 0.98                 | 4.64 ± 1.86             | 12.22 ± 2.79     | 50.00        |
| III    | 6  | 4.29 ± 0.66 **     | 1.83 ± 0.31 *                            | 100 **                   | 5.17 ± 0.54                 | 7.38 ± 2.63             | 11.74 ± 3.22     | 66.67 **     |
| IIIf   | 6  | 3.63 ± 1.17 **     | 2.67 ± 0.92                               | 100 **                   | 4.67 ± 0.62                 | 8.39 ± 2.74             | 10.59 ± 4.42     | 50.00        |
| IIg    | 6  | 3.43 ± 0.46 **     | 2.00 ± 0.52                               | 100 **                   | 5.00 ± 0.63                 | 7.06 ± 5.33             | 13.72 ± 7.55     | 66.67 **     |
| IIh    | 6  | 14.81 ± 9.17       | 2.50 ± 0.76                               | 83.33                    | 4.50 ± 0.96                 | 8.45 ± 3.99             | 15.34 ± 5.02     | 50.00        |
| IIi    | 6  | 6.37 ± 2.05 #      | 2.00 ± 0.52                               | 83.33                    | 4.50 ± 0.50                 | 2.93 ± 1.99 *           | 11.38 ± 4.18     | 33.33 *      |

SV—Sodium valproate; data are given as (M ± m); * p < 0.05; ** p < 0.01 compared to the control; # p < 0.05; ## p < 0.01 compared to sodium valproate.
At the second stage, the most active compounds Ib, Id, and Ij were selected to evaluate their anticonvulsant action in the MES model. The results of the experiment are shown in the Table 2. Carbamazepine was used as a reference drug, due to its ability to block sodium channels that play a leading role in the development of primary-generalized convulsions [57]. There was a significant reduction of the severity of the convulsion by 1.2 times (4.78 ± 0.28 vs. 5.53 ± 0.13 points, \( p < 0.05 \)), the duration of the convulsive period by 2.4 times (0.10 ± 0.03 vs. 0.24 ± 0.03 min, \( p < 0.01 \)) and the duration of the recovery period by 1.9 times (0.41 ± 0.14 vs. 0.80 ± 0.16 min, \( p < 0.01 \)) under carbamazepine treatment.

Table 2. Anticonvulsant effect of tested compounds in MES model.

| Group | n | % of Mice with Seizures | Seizures, Points | Period of Seizures, min | Recovery Period (Lateral Position), min | Ttime to Death, min | Mortality, % |
|-------|---|-------------------------|------------------|------------------------|----------------------------------------|--------------------|-------------|
| Control | 17 | 100 | 100 | 5.53 ± 0.13 | 0.24 ± 0.03 | 0.80 ± 0.16 | 0.30 ± 0.03 | 52.94 |
| CM | 14 | 100 | 92.86 | 4.78 ± 0.28 * | 0.10 ± 0.03 ** | 0.41 ± 0.14 ** | 0.32 ± 0.02 | 35.71 |
| Ib | 14 | 100 | 78.57 ** | 4.57 ± 0.33 * | 0.08 ± 0.03 ** | 0.27 ± 0.27 ** | 0.28 ± 0.03 | 35.71 |
| Id | 14 | 100 | 85.71 * | 5.00 ± 0.33 | 0.13 ± 0.03 * | 0.23 ± 0.03 ** | 0.30 ± 0.02 | 57.14 |
| Ij | 14 | 100 | 78.57 ** | 4.71 ± 0.34 | 0.10 ± 0.03 ** | 0.32 ± 0.10 ** | 0.26 ± 0.01 | 42.86 |

CM—carbamazepine; data are given as (M ± m); * \( p < 0.05 \); ** \( p < 0.01 \). Compared to the control.

Compound Ij reduced the percentage of animals with tonic seizures (78.57% vs. 100%, \( p < 0.01 \)) and decreased the duration of tonic and clonic seizures by 2.4 and 2.5 times respectively (0.10 ± 0.03 vs. 0.24 ± 0.03 min and 0.32 ± 0.10 vs. 0.80 ± 0.16 min, \( p < 0.01 \)). Under compound Id action reduction of the percentage of mice with tonic seizures by 14.3% (85.71 vs. 100%, \( p < 0.05 \)), decreasing of the duration of tonic extension by 1.8 times (0.13 ± 0.03 vs. 0.24 ± 0.03 min, \( p < 0.05 \)) and clonic convulsions by 3.5 times (0.23 ± 0.03 vs. 0.80 ± 0.16 min, \( p < 0.01 \)) were observed. Compound Ib significantly decreased the amount of mice with tonic seizures by 21.4% (78.57% vs. 100%, \( p < 0.01 \)), the duration of tonic extension and clonic seizures by 3 and 2.9 times, respectively (0.08 ± 0.03 vs. 0.24 ± 0.03 min and 0.27 ± 0.27 vs. 0.80 ± 0.16 min, \( p < 0.01 \)), and the severity of convulsions by 1.2 times (4.57 ± 0.33 vs. 5.53 ± 0.13 points, \( p < 0.05 \)). Thus, all three compounds possess the anticonvulsant properties in the MES model, the compounds’ activities was not inferior to carbamazepine.

The most active of the synthesized compounds were evaluated for their approximate LD₅₀ (intraperitoneal administration) in mice [46,47]. Tested compounds were relatively non-toxic and well tolerated by the experimental animals as demonstrated by their LD₅₀ (Ib—263 ± 27.1 mg/kg, Id—610 ± 40.5 mg/kg, Ij—320 ± 31.5 mg/kg).

The analysis of the structure-activity relationships in the group of 2-imino-4-thiazolidinones (I) revealed the following patterns: The presence of nitrobenzylidene fragment at C5 position of main core are preferred for anticonvulsant activity realization. The replacement of the nitro-group by fluorine atom (compound Ia) or dimethylamino group (compound Ic) led to reduction of the anticonvulsant effect. The introduction of the substituent in the N3 position of the thiazolidinone core led to only imino-form of compounds and the impossibility of amino-iminotautomeric transformation. Such modification of 2-iminothiazolyl-4-thiazolidinones led to a decrease of anticonvulsant activity (compound Ie). The replacement of the arylidene fragment by isatine moiety that can be treated as annulation of benzylidene fragment (compound Id), and it was not the optimal direction for compound structure modification. Compound Id possesses even pro-convulsant activity. For such group of compounds I with different substituent in the C5 benzylidene fragment the strong antimicrobial activity [43,58] and inhibition of SHP-2 (non receptor protein tyrosine phosphatase that mediates cell signaling by growth factors and cytokines acting via the RAS/MAP kinase pathway [59]) also was detected. These alone with a new trend in the creation of new anticonvulsants [60] can be treated as a benefit, especially within a polypharmacological approach [10,11], when the compound possessed several types of activity and can be used as a baseline for further optimization.
For the 2,4-thiazolidinone-5-carboxylic acid derivatives (II), the next aspects of structure-activity relationships were funded: The complication of C5 moiety (compounds IIh and IIi) led to activity decreasing; the presence of N3 substituent was essential (crucial decreasing of activity of IIf compare to IIj). The nature of the substituents in the N3 fragment also plays a significant role: The absence of C=O group (compound IIb), as well as the replacement of CF3 (IId) group by OMe group (IIc) provided the activity decreasing. Saturated analogs (with C5-single bond) of compound IIj also possessed the strong anticonvulsant activity [61] that confirmed the potency of such direction for the new anticonvulsants design.

Hit-compounds Ib, IId, and IIj showed pronounced anticonvulsant properties in both the PTZ-model and the MES-test. It can be assumed that these compounds have a mixed mechanism of action aimed at increasing the inhibitory processes in the central nervous system by increasing GABA-ergic activity, and reducing the processes of excitation in the CNS by blocking the sodium channels. The results of the study provide a basis for further study of the anticonvulsant properties of thiazole-thiazolidinones.

4. Conclusions

The present work reports the design and synthesis, and anticonvulsant activity evaluation of two series of thiazole-bearing 4-thiazolidinones, namely 2-imino-4-thiazolidinones and 2,4-dioxothiazolidine-5-carboxamides. The design of the compounds’ structure was based on structural requirements for anticonvulsant structures, similarity to ralitoline—known anticonvulsant drug, and a combination of two azole cores. The study of the anticonvulsant activity was undertaken in pentyleneetetrazole-induced seizures assay and maximal electroshock seizure test. Among the tested compounds 5Z-(3-nitrobenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one Ib, 2-[2,4-dioxo-5-(thiazol-2-ylcarbamoylmethyl)-thiazolidin-3-yl]-N-(2-trifluoromethylphenyl)-acetamide IId, and [2,4-dioxo-5-(thiazol-2-ylcarbamoylmethylene)-thiazolidin-3-yl]-acetic acid ethyl ester IIj showed excellent anticonvulsant activity in both assays and possessed relatively low acute toxicity. Some structure-activity relationship findings were discussed as well as directions for such compounds modification. The results of the study provide a basis for further study of the anticonvulsant properties of selected thiazole-thiazolidinone hybrids.

Author Contributions: Conceptualization, D.K. and R.L.; design and synthesis of compounds D.K. and R.L.; pharmacological study M.M. and S.S.; writing—Original draft preparation, D.K. and S.S.; writing—Review and editing, D.K., R.L., M.M., S.S. All authors have read and agreed to the published version of the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Forsgren, L.; Beghi, E.; Oun, A.; Sillanpää, M. The epidemiology of epilepsy in Europe—A systematic review. *Eur. J. Neurol.* 2005, 12, 245–253. [CrossRef] [PubMed]
2. World Health Organization. Fact Sheets: Epilepsy. Available online: http://www.who.int/ru/news-room/fact-sheets/detail/epilepsy (accessed on 27 December 2019).
3. Galiana, G.L.; Gauthier, A.C.; Mattson, R.H. Eslicarbazepine acetate: A new improvement on a classic drug family for the treatment of partial-onset seizures. *Drugs R D* 2017, 17, 329–339. [CrossRef]
4. Frampton, J.E. Perampanel: A review in drug-resistant epilepsy. *Drugs* 2015, 75, 1657–1668. [CrossRef] [PubMed]
5. Gunthorpe, M.J.; Large, C.H.; Sankar, R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. *Epilepsia* 2012, 53, 412–424. [CrossRef] [PubMed]
6. Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen Hauser, W.; Mathern, G.; French, J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010, 51, 1069–1077. [CrossRef]
7. Devinsky, O. Patients with refractory seizures. *N. Engl. J. Med.* 1999, 340, 1565–1570. [CrossRef]
8. Hu, Q.; Zhang, F.; Teng, W.; Hao, F.; Zhang, J.; Yin, M.; Wang, N. Efficacy and safety of antiepileptic drugs for refractory partial-onset epilepsy: A network meta-analysis. J. Neurol. 2018, 265, 1–11. [CrossRef]
9. Perucca, P.; Gilliam, F.G. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012, 11, 792–802. [CrossRef]
10. Kaminskyy, D.; Kryschchyn, A.; Lesyk, R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin. Drug Dis. 2017, 12, 1233–1252. [CrossRef]
11. Kaminskyy, D.; Kryschchyn, A.; Lesyk, R. 5-Ene-4-thiazolidinones—An efficient tool in medicinal chemistry. Eur. J. Med. Chem. 2017, 140, 542–594. [CrossRef]
12. Gong, G.H.; Wang, D.; Zhang, J.F.; Wei, C.X.; Quan, Z.S. Anticonvulsant activity of 2-(substituted-imino) thiazolidin-4-ones. Drug Res. 2014, 64, 5–9. [CrossRef] [PubMed]
13. Senthilraj, M.; Alagarsamy, V. Synthesis and pharmacological investigation of 2-(4-dimethylaminophenyl)-3,5-disubstituted thiazolidin-4-ones as anticonvulsants. Arch. Pharm. 2012, 345, 827–833. [CrossRef] [PubMed]
14. Themnozhijal, J.C.; Wong, P.T.; Chui, W.K. Anticonvulsant activity of phenylmethylenhydantoins: A structure-activity relationship study. J. Med. Chem. 2004, 47, 1527–1535. [CrossRef] [PubMed]
15. Taroua, M.; Ribuot, C.; Pera, M.H.; Taillandier, G.; Fatome, M.; Laval, J.D.; Leclerc, G. New α, β and γ semicarbazone and thiosemicarbazone 1,3-dithiolanes as radioprotectors. Anticonvulsant activity. Eur. J. Med. Chem. 1996, 31, 589–595. [CrossRef]
16. Pandeya, S.N.; Yogeesswari, P.; Stables, J.P. Synthesis and anticonvulsant activity of 4-bromophenyl substituted aryl semicarbazides. Eur. J. Med. Chem. 2000, 35, 879–886. [CrossRef]
17. Sun, Q.; Tafesse, L.; Limberis, J.T.; Islam, K.; Kyle, D.J. Parallel synthesis of a biased library of thiazolidinones as novel sodium channel antagonists. Comb. Chem. High Throughput Screen 2003, 6, 481–488. [CrossRef]
18. Amin, K.M.; Rahman, D.E.A.; Al-Eryani, Y.A. Synthesis and preliminary evaluation of some substituted coumarins as anticonvulsant agents. Bioorg. Med. Chem. 2008, 16, 5377–5388. [CrossRef]
19. Ghogare, J.G.; Bhandari, S.V.; Bothara, K.G.; Madgulkar, A.R.; Parashar, G.A.; Sonawane, B.G.; Inamdar, P.R. Design, synthesis and pharmacological screening of potential anticonvulsant agents using hybrid approach. Eur. J. Med. Chem. 2010, 45, 857–863. [CrossRef]
20. Malawaska, B. New anticonvulsant agents. Curr. Top. Med. Chem. 2005, 5, 69–85. [CrossRef]
21. Mullick, P.; Khan, S.A.; Verma, S.; Alam, O. Thiazidazole derivatives as potential anticonvulsant agents. Bull. Korean Chem. Soc. 2011, 32, 1011–1016. [CrossRef]
22. Myronenko, S.I.; Kaminsky, D.V.; Nektsegayev, I.O.; Pinyazko, O.R.; Lesyk, R.B. Search of new anticonvulsant agents among 4-thiazolidinones and related heterocyclic systems. Clin. Pharm. Pharmacother. Med. Standart 2012, 1–2, 124–131.
23. Rajak, H.; Deshmukh, R.; Veerasamy, R.; Sharma, A.K.; Mishra, P.; Kharya, M.D. Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: One more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity. Bioorg. Med. Chem. Lett. 2010, 20, 4168–4172. [CrossRef] [PubMed]
24. Angelova, V.T.; Vojnikov, Y.; Andreeva-Gateva, P.; Surcheva, S.; Vassilev, N.; Pencheva, T.; Tchekalarova, J. In vitro and in silico evaluation of chromene based aroylhydrazones as anticonvulsant agents. Med. Chem. Res. 2017, 26, 1884–1896. [CrossRef]
25. Al-Otaibi, F. An overview of structurally diversified anticonvulsant agents. Acta Pharm. 2019, 69, 321–344. [CrossRef]
26. Kumar, A.; Mishra, A.K. Design, molecular docking, synthesis, characterization, biological activity evaluation (against MES model), in-silico biological activity spectrum (PASS analysis), toxicological and predicted oral rat LD 50 studies of novel sulphonamide derivatives. Front. Biol. 2018, 13, 425–451. [CrossRef]
27. Shiradkar, M.R.; Ghodake, M.; Bothara, K.G.; Bhandari, S.V.; Nikalje, A.; Akula, K.C.; Desai, N.C.; Burange, P.J. Synthesis and anticonvulsant activity of clubbed thiazolidinone–barbituric acid and thiazolidinone-triazole derivatives. Arkivoc 2007, 14, 58–74. [CrossRef]
28. Faizi, M.; Jahan, R.; Ebadi, S.A.; Tabatabai, S.A.; Rezaee, E.; Lotfaliei, M.; Amiri, M.; Almasirad, A. Novel 4-thiazolidinone derivatives as agonists of benzodiazepine receptors: Design, synthesis and pharmacological evaluation. EXCLI J. 2017, 16, 52–62. [CrossRef]
29. Nikalje, A.P.G.; Shaikh, A.N.; Shaikh, S.I.; Khan, F.A.K.; Sangshetti, J.N.; Shinde, D.B. Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamidine derivatives as anticonvulsant agents. Bioorg. Med. Chem. Lett. 2014, 24, 5558–5562. [CrossRef]
54. Kaminskyy, D.; Zimenkovsky, B.; Lesyk, R. Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives. *Eur. J. Med. Chem.* **2009**, *44*, 3627–3636. [CrossRef]

55. Stables, J.P.; Kupferberg, H.J. The NIH Anticonvulsant Drug Development (ADD) Program: Preclinical anticonvulsant screening project. In *Molecular and Cellular Targets for Anti-Epileptic Drugs*; Avarzini, G., Tanganelli, P., Avoli, M., Eds.; John Libbey& Co.: London, UK, 1997; pp. 191–198.

56. Mula, M. GABAergic drugs in the treatment of epilepsy: Modern or out moded? *Future Med. Chem.* **2011**, *3*, 177–182. [CrossRef] [PubMed]

57. Właż, P.; Rolinski, Z.; Kleinrok, Z.; Czuczwar, S.J. Anticonvulsant activity of carbamazepine and diphenylhydantoin against maximal electroshock in mice chronically treated with aminophylline. *J. Neur. Trans.* **1992**, *89*, 41–48. [CrossRef] [PubMed]

58. Vicini, P.; Geronikaki, A.; Incerti, M.; Zani, F.; Dearden, J.; Hewitt, M. 2-Heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: Synthesis and structure–activity relationship. *Bioorg. Med. Chem.* **2008**, *16*, 3714–3724. [CrossRef] [PubMed]

59. Geronikaki, A.; Eleftheriou, P.; Vicini, P.; Alam, I.; Dixit, A.; Saxena, A.K. 2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. *J. Med. Chem.* **2008**, *51*, 5221–5228. [CrossRef]

60. Löscher, W. Strategies for antiepileptogenesis: Antiepileptic drugs versus novel approaches evaluated in post-status epilepticus models of temporal lobe epilepsy. In *Jasper’s Basic Mechanisms of the Epilepsies*, 4th ed.; National Center for Biotechnology Information: Bethesda, MA, USA, 2012. Available online: https://www.ncbi.nlm.nih.gov/books/NBK98148/ (accessed on 1 March 2020).

61. Lesyk, R.B.; Pinyazko, O.R.; Myronenko, S.I.; Nektegayev, I.O. Patent UA112347 U Ethyl-2-[2,4-dioxo-5-[2-oxo-2-(Thiazol-2-ylamino)ethyl]Thiazolidin-3-yl]Acetate, Which Possessed Anticonvulsant Activity. Date of Application 17.06.2016; Published 12.12.2016, Bul.Nr 23. Available online: https://sis.ukrpatent.org/uk/search/detail/822102/ (accessed on 1 March 2020). (In Ukrainian).